Susquehanna International Group, LLP Cara Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 127,553 shares of CARA stock, worth $39,541. This represents 0.0% of its overall portfolio holdings.

Number of Shares

127,553

Previous 185,847 31.37%

Holding current value

$39,541

Previous $48,000 18.75%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.26 - $0.38 $15,156 - $22,151	-58,294 Reduced 31.37%	127,553 $39,000
Q2 2024 Aug 15, 2024	BUY	$0.24 - $0.92 $29,767 - $114,109	124,032 Added 200.65%	185,847 $48,000
Q1 2024 May 07, 2024	BUY	$0.52 - $1.05 $8,391 - $16,943	16,137 Added 35.33%	61,815 $56,000
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.65 $144,843 - $398,319	-241,406 Reduced 84.09%	45,678 $33,000
Q3 2023 Nov 14, 2023	BUY	$1.67 - $3.33 $47,783 - $95,281	28,613 Added 11.07%	287,084 $482,000
Q2 2023 Aug 11, 2023	BUY	$2.83 - $4.94 $577,936 - $1.01 Million	204,218 Added 376.42%	258,471 $731,000
Q1 2023 May 16, 2023	BUY	$4.89 - $12.27 $265,297 - $665,684	54,253 New	54,253 $266,000
Q3 2022 Nov 14, 2022	SELL	$8.24 - $12.56 $58,973 - $89,891	-7,157 Reduced 9.61%	67,326 $630,000
Q2 2022 Aug 15, 2022	BUY	$7.45 - $13.84 $118,775 - $220,651	15,943 Added 27.23%	74,483 $680,000
Q1 2022 May 16, 2022	SELL	$9.94 - $12.65 $2.24 Million - $2.85 Million	-225,428 Reduced 79.39%	58,540 $711,000
Q4 2021 Feb 14, 2022	BUY	$11.99 - $18.14 $772,371 - $1.17 Million	64,418 Added 29.34%	283,968 $3.46 Million
Q3 2021 Nov 15, 2021	BUY	$11.55 - $16.06 $1.06 Million - $1.47 Million	91,832 Added 71.9%	219,550 $3.39 Million
Q2 2021 Aug 11, 2021	BUY	$12.38 - $29.19 $1.17 Million - $2.76 Million	94,680 Added 286.58%	127,718 $1.82 Million
Q1 2021 May 17, 2021	SELL	$15.07 - $21.71 $241,135 - $347,381	-16,001 Reduced 32.63%	33,038 $717,000
Q4 2020 Feb 16, 2021	SELL	$12.72 - $16.16 $268,608 - $341,250	-21,117 Reduced 30.1%	49,039 $742,000
Q3 2020 Nov 16, 2020	SELL	$12.34 - $17.92 $129,977 - $188,751	-10,533 Reduced 13.05%	70,156 $893,000
Q1 2020 May 15, 2020	SELL	$9.12 - $17.78 $394,494 - $769,091	-43,256 Reduced 34.9%	80,689 $1.07 Million
Q4 2019 Feb 14, 2020	BUY	$16.11 - $25.98 $1.12 Million - $1.81 Million	69,687 Added 128.44%	123,945 $2 Million
Q3 2019 Nov 14, 2019	SELL	$18.28 - $26.91 $5.88 Million - $8.65 Million	-321,614 Reduced 85.56%	54,258 $992,000
Q2 2019 Aug 16, 2019	BUY	$17.68 - $21.57 $206,820 - $252,325	11,698 Added 3.21%	375,872 $8.08 Million
Q2 2019 Aug 14, 2019	BUY	$17.68 - $21.57 $2.54 Million - $3.09 Million	143,392 Added 64.95%	364,174 $7.83 Million
Q1 2019 May 15, 2019	SELL	$14.41 - $19.64 $598,130 - $815,217	-41,508 Reduced 15.83%	220,782 $4.33 Million
Q4 2018 Feb 14, 2019	SELL	$12.45 - $23.47 $1.74 Million - $3.29 Million	-140,113 Reduced 34.82%	262,290 $3.41 Million
Q3 2018 Nov 14, 2018	BUY	$17.57 - $23.95 $3.95 Million - $5.39 Million	224,859 Added 126.65%	402,403 $9.64 Million
Q2 2018 Aug 14, 2018	SELL	$11.6 - $19.27 $1.31 Million - $2.18 Million	-113,323 Reduced 38.96%	177,544 $3.4 Million
Q1 2018 May 15, 2018	SELL	$11.77 - $16.08 $377,687 - $515,991	-32,089 Reduced 9.94%	290,867 $3.6 Million
Q4 2017 Feb 14, 2018	BUY	$11.86 - $14.08 $2.27 Million - $2.7 Million	191,416 Added 145.52%	322,956 $3.95 Million
Q3 2017 Nov 14, 2017	BUY	$12.6 - $16.34 $1.66 Million - $2.15 Million	131,540	131,540 $1.8 Million

Others Institutions Holding CARA

# of Institutions

Shares Held

12.8M

Call Options Held

Put Options Held

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $16.7M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Cara Therapeutics, Inc. Transaction History